2023
DOI: 10.1007/s15010-023-02011-0
|View full text |Cite
|
Sign up to set email alerts
|

Seroprevalence trends of anti-SARS-CoV-2 antibodies and associated risk factors: a population-based study

Abstract: Purpose We aimed to assess the seroprevalence trends of SARS-CoV-2 antibodies in several Swiss cantons between May 2020 and September 2021 and investigate risk factors for seropositivity and their changes over time. Methods We conducted repeated population-based serological studies in different Swiss regions using a common methodology. We defined three study periods: May–October 2020 (period 1, prior to vaccination), November 2020–mid-May 2021 (period 2, f… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
4
1

Relationship

2
3

Authors

Journals

citations
Cited by 5 publications
(2 citation statements)
references
References 32 publications
0
2
0
Order By: Relevance
“…This study has some limitations. Firstly, despite a random representative sample of the population being invited, selection bias is probable (e.g., a lower participation of low SES individuals or over-representation of individuals with a low SES and a high health literacy), also due to moderate participation rate (21%) of the Corona Immunitas study [ 41 ]. Additionally, our study relied on a baseline assessment of predictors, and we lacked information about potential changes in equivalized disposable income over time.…”
Section: Discussionmentioning
confidence: 99%
“…This study has some limitations. Firstly, despite a random representative sample of the population being invited, selection bias is probable (e.g., a lower participation of low SES individuals or over-representation of individuals with a low SES and a high health literacy), also due to moderate participation rate (21%) of the Corona Immunitas study [ 41 ]. Additionally, our study relied on a baseline assessment of predictors, and we lacked information about potential changes in equivalized disposable income over time.…”
Section: Discussionmentioning
confidence: 99%
“…The laboratory-confirmed SARS-CoV-2 cases are obtained from the Federal Office of Public Health. The serosurvey was performed by the Corona Immunitas Research Group in Switzerland [ 52 ]. As the seroprevalence data were collected over a prolonged period, we decided to use monthly seroprevalence estimates for fitting the model.…”
Section: Methodsmentioning
confidence: 99%